SEC Form 4 · accession 0001127602-19-010841
Moderna, Inc. · MRNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer Ling Lee
Officer — Chief Accounting Officer
Period of report
Mar 8, 2019
Accepted (ET)
Mar 11, 2019 · 5:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001682852
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 8, 2019 | A | 4,780 | $0.00 | A | 4,780 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $20.93 | Mar 8, 2019 | A | 25,097 | A | Mar 8, 2020 | Mar 8, 2029 | Common Stock | 25,097 | 25,097 | D |
Explanation of responses
- F125% of the shares subject to this restricted stock unit award will vest on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
- F225% of this option will vest and become exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.